Maximilian Joseph Brol
Overview
Explore the profile of Maximilian Joseph Brol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trebicka J, Aguilar F, Farias A, Lozano J, Sanchez-Garrido C, Uson-Raposo E, et al.
Gut
. 2025 Feb;
PMID: 40011033
Background And Aims: Quantifying systemic inflammation (SI) in acutely decompensated cirrhosis (ADC) is of major importance because SI is a driver of the most severe forms of ADC, including acute-on-chronic...
2.
Kraus N, Uschner F, Moeslein M, Schierwagen R, Gu W, Brol M, et al.
Cells
. 2024 Oct;
13(20.
PMID: 39451225
Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models...
3.
Gu W, de Ledinghen V, Aube C, Krag A, Strassburg C, Castera L, et al.
NEJM Evid
. 2024 Oct;
3(11):EVIDoa2400062.
PMID: 39437136
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the...
4.
5.
Thiele M, Villesen I, Niu L, Johansen S, Sulek K, Nishijima S, et al.
J Hepatol
. 2024 Mar;
81(2):345-359.
PMID: 38552880
The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and...
6.
Brol M, Drebber U, Yu X, Schierwagen R, Gu W, Plamper A, et al.
Surg Obes Relat Dis
. 2024 Mar;
20(8):759-766.
PMID: 38522962
Background: Obesity and nonalcoholic fatty liver disease (NAFLD) are an increasing health care burden worldwide. Weight loss is currently the best option to alleviate NAFLD and is efficiently achieved by...
7.
Bartimoccia S, Praktiknjo M, Nocella C, Schierwagen R, Cammisotto V, Jansen C, et al.
Intern Emerg Med
. 2024 Feb;
19(3):713-720.
PMID: 38409619
Pathophysiology of portal vein thrombosis (PVT) in cirrhosis is still not entirely understood. Elevated levels of lipopolysaccharides (LPS) in portal circulation are significantly associated with hypercoagulation, increased platelet activation and...
8.
Gu W, Zeleke Y, Hortlik H, Schaaf L, Uschner F, Schulz M, et al.
Hepatol Commun
. 2023 Sep;
7(10).
PMID: 37708430
Background: The number of complications in patients admitted for cirrhosis has increased over time. Portal hypertension is the driver of many complications of cirrhosis. TIPS placement is the most effective...
9.
Ruiz-Margain A, Pohlmann A, Lanzerath S, Langheinrich M, Campos-Murguia A, Roman-Calleja B, et al.
JHEP Rep
. 2023 Aug;
5(8):100761.
PMID: 37554924
Background & Aims: Acute-on-chronic liver failure (ACLF) has been linked to different pathophysiological mechanisms, including systemic inflammation and mitochondrial dysfunction. Sarcopenia has also been proposed as a potential mechanism; myostatin...
10.
Rheinwalt K, Fobbe A, Plamper A, Alizai P, Schmitz S, Brol M, et al.
Langenbecks Arch Surg
. 2023 Feb;
408(1):74.
PMID: 36729181
Purpose: Roux-en-Y gastric bypass (RYGB) and one anastomosis gastric bypass (OAGB) are effective standard bariatric surgeries with comparable weight loss and remission of obesity-related comorbidities. As procedure-specific health-related quality of...